1Song JJ, Lee H, Kim E, et al. Transduction effect of antisense Kras on malignant phenotypes in gastric cancer cells [J]. Cancer Lett, 2000, 157 (1): 1-7.
2Driscoll B, Wu L, Buckley S, et al. Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth [J]. Am J Physiol, 1997, 273 (5 Pt 1): L941-949.
3Sauter ER, Nesbit M, Litwin S, et al. Antisense cyclin D1 induces apoptosis and timor shrinkage in human squamous carcinomas [J]. Cancer Res, 1999, 59 (19): 4876-4881.
4Kornmann M, Arber N, Kore M. Inhibition of basal and mitogenstimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum [J]. J Clin Invest, 1998, 101(2): 344-352.
6Annab LA, Hawkins RE, Solomon G, et al. Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line [J]. Breast Cancer Res, 2000, 2 (2) : 139-148.
8Hirao T, Sawada H, Koyama F, et al. Antisense epidermal growth factor receptor delivered by adenorival vector blocks tumor growth in human gastric cancer [J]. Cancer Gene Ther, 1999, 6 (5): 423-427.
9Wang HM, Rajagopal S, Chakrabarty S. Inhibition of human colon cancer malignant cell behavior and growth by antisense epidermal growth factor receptor expression vector [J]. Anticancer Res, 1998, 18 (4A): 2297-2300.
10Chernicky CL, Yi L, Tan H, et al. Treatment of human breast cancer cells with antisense RNA to the type Ⅰ insulin-like growth factor receptor inhubits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo [J]. Cancer Gene Ther, 2000,7(3) : 384-395.
